Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer

Next Previous
Trial Profile

A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SGX 523 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors SGX Pharmaceuticals

    • Most Recent Events

    • 22 Jul 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 May 2008 Further drug development discontinued due to observed toxicities, according to an SGX Pharmaceuticals media release.
    • 27 Mar 2008 Dose limiting toxicity was observed earlier than anticipated; no patients are currently being treated in the interrupted dose trial and patient are continuing treatment at the lower dose level in the continuous dosing trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top